Comparison of Cytochrome P450 2C Subfamily Members in Terms of Drug Oxidation Rates and Substrate Inhibition

ISSN: 1875-5453 (Online)
ISSN: 1389-2002 (Print)

Volume 18, 12 Issues, 2017

Download PDF Flyer

Current Drug Metabolism

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 125th of 289 in Biochemistry & Molecular Biology
  • 82nd of 254 in Pharmacology & Pharmacy

Submit Abstracts Online Submit Manuscripts Online

Michael Sinz
Bristol Myers Squibb
Wallingford, CT

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.847
5 - Year: 3.222

Comparison of Cytochrome P450 2C Subfamily Members in Terms of Drug Oxidation Rates and Substrate Inhibition

Current Drug Metabolism, Volume 13 (E-pub ahead of print)

Author(s): Toshiro Niwa and Hiroshi Yamazaki.

Affiliation: Showa Pharmaceutical University, 3-3165 Higashi-tamagawa Gakuen, Machida, Tokyo 194-8543, Japan


This review focuses on identification of important active-site residues of the cytochrome P450 2C (CYP2C) subfamily in terms of substrate specificity. A meta-analysis was performed on the reported literature regarding (1) values of the Michaelis-Menten constant (Km), maximal velocity (Vmax), and intrinsic clearance (Vmax/Km) for 74 metabolic reactions of 45 substrates mediated by human CYP2C8, CYP2C9, CYP2C18, and CYP2C19 and (2) inhibition constants (Ki) for 3 inhibitors. Although the kinetic behaviors of these CYP2C subfamily members depend on the metabolic reaction, the ratios of Vmax/Km values for CYP2C19/CYP2C9 and CYP2C8/CYP2C19, but not for CYP2C8/CYP2C9, were more closely correlated with Km values than with Vmax values, suggesting that, for many metabolic reactions, differences in affinity may be more important than differences in capacity for the substrate/reaction specificity of the CYP2C subfamily, especially for CYP2C19. In addition, it has been proposed that the residues involved in substrate recognition sites (SRS) 1, SRS 3, and/or SRS 4 are important for the metabolizing capacity and/or the substrate binding of CYP2C9 and CYP2C19. In contrast to the reasonable amount of kinetic data available, there are few reports comparing the effects of inhibitors [inhibitory constant (Ki) or 50% inhibitory concentration (IC50)] on metabolic reactions mediated by the CYP2C subfamily. Collectively, these findings provide insights into the contributions of CYP2C subfamily members to drug metabolism and adverse drug interactions.


CYP2C8, CYP2C9, CYP2C18, CYP2C19, meta-analysis, metabolic activity, inhibition constant.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 13
Price: $95

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science